Likelihood of Approval and Phase Transition Success Rate Model – Retlirafusp Alfa in Gastric Cancer
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Retlirafusp Alfa in Gastric Cancer report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Retlirafusp Alfa in Gastric Cancer Drug Details:
SHR-1701 is under development for the treatment of advanced unresectable or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma, metastatic pancreatic cancer, recurrent or metastatic cervical cancer, advanced melanoma, relapsed and refractory solid tumors including metastatic colorectal cancer (mCRC), squamous cell or non-squamous non-small cell lung cancer, recurrent or metastatic squamous cell carcinoma of the head and neck, advanced pancreatic cancer, hepatocellular carcinoma, rectal cancer, biliary tract cancer and recurrent or metastatic nasopharyngeal carcinoma. The therapeutic candidate is administered as intravenous drip. It is a bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD L1) fused with the extracellular domain of TGFbeta receptor II.It was also under development for the treatment of small cell lung cancer and renal cell carcinoma.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Retlirafusp Alfa LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports